Navigation Links
Relieving chronic pain

Each year, more than 35,000 patients in the United States are implanted with spinal cord stimulators to treat chronic pain. Unfortunately, up to half of such patients receive only very limited pain relief. To help more patients, scientists are developing a new device to deliver therapeutic stimulation in a more targeted way, reaching nerve fibers deep within the spinal cord.

Standard devices, first introduced in 1967, work by delivering a low electrical current to the spinal cord that interferes with the body's pain signals. Such devices, however, are only able to deliver therapeutic current to a thin layer of nerve fibers along the outside of the spinal cord. That's because the electrodes delivering the current are placed within the cerebrospinal fluid, which is itself conductive and so dissipates some of the current.

The new device, called the Human Spinal Cord Modulation System (HSCMS), is designed to be in direct contact with the spinal cord, held in place by a small loop of wire. Because the spinal cord moves during normal patient activity, that loop has to exert enough pressure for the HSCMS to stay in contact with the spinal cord but not so much that the pressure restricts blood flow or causes direct injury.

To test the pressure exerted by the HSCMS's design, researchers attached the device to a silicone model of the spinal cord previously developed to have the same biomechanical characteristics as living tissue. They then slowly compressed the loop, measuring the pressure exerted on the silicone model. The results, which were accepted for publication in the American Institute of Physics (AIP) Journal of Applied Physics, show the device's loop design exerts pressure at a similar level as is normally found on the spinal cords of healthy people, and so passes an important safety test for further development of the device.

Contact: Catherine Meyers
American Institute of Physics

Page: 1

Related biology news :

1. Relieving plant stress could eventually help humans relax
2. Are survivors of childhood leukemia and lymphoma at greater risk of chronic fatigue as adults?
3. NIH awards nearly $2 million to 3 NYC institutions for chronic fatigue syndrome research
4. Preventing chronic pain with stress management
5. Virology researcher awarded nearly $2 million to study chronic hepatitis E
6. Loneliness, like chronic stress, taxes the immune system
7. Chronic disease research awarded funding
8. Social synchronicity
9. Chronic kidney disease increases risk of death at all ages
10. Viruses not to blame for chronic fatigue syndrome after all
11. B cell survival holds key to chronic graft vs. host disease
Post Your Comments:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology: